sumitomo dainippon pharma co
(4506:Tokyo Stock Exchange)
Mark T. Iwicki
Former Executive officer, Sumitomo Dainippon Pharma Co., Ltd.
|Age||Total Calculated Compensation||This person is connected to 76 board members in 8 different organizations across 9 different industries.|
See Board Relationships
Mr. Mark T. Iwicki served as the Chief Executive Officer and President of Civitas Therapeutics, Inc. since January 29, 2014. Mr. Iwicki has more than 23 years of experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas. He has extensive experience managing high-performance teams and is instrumental in the success of a number of drugs, including Prilosec, Diovan, Zelnorm, Lunesta, and Latuda. He served as President ...
6-8 Doshomachi 2-chomePhone: 81 6 6203 5321
Osaka, -- 541-0045
Fax: 81 6 6202 6028
Board Members Memberships*
Director and Member of Audit Committee
Loyola University Maryland
Ball State University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|There is no Competitor Compensation data available.|